Introduction
Pancreatic adenocarcinoma (PDA) has the worst prognosis of any major malignancy, with 5-year survival of about 5% (1, 2) and is one of the most chemotherapy and radiotherapy resistant tumors (2, 3) . PDA is characterized by very dense stroma that makes up anywhere from 60% to 90% of the total tumor volume (4) . The stromal compartment is made up of variety of different cells and proteins that act together to develop an environment that is suppressive to the immune system, drug resistant and protumorigenic (5) . Although there have been numerous new therapies developed for other cancers, little progression has been made finding new therapies for PDA despite promising results from pre-clinical studies.
It is well documented that c-Met receptor and its ligand HGF are upregulated in PDA (6) . Upregulation of c-Met and HGF is detected early in PDA development and promotes tumorigenesis in conjunction with other oncogenic signals (7) . Because HGF is exclusively secreted by stromal fibroblasts (8) and stromal expression of HGF was correlated with decreased disease free survival (9) , activation of c-Met in neoplastic cells is believed to be subject to the regulation of signals from the stroma. More recently, HGF/c-Met has been investigated as a therapeutic target for PDA. The combination of gemcitabine and crizotinib, a small molecule c-Met inhibitor, was tested in murine models and was shown to enhance the intratumoral delivery of gemcitabine and result in tumor reduction of the PDA xenograft (10) variety of solid cancers (10) . Unfortunately, the phase II trial of cabozantinib showed minimal benefits in patients with PDA, despite promising results in subjects with other solid tumors (12, 13) .
The hedgehog (Hh) pathway, specifically the activating ligand, Sonic hedgehog (Shh), is overexpressed by PDA tumor cells; however its function is restricted to the stromal compartment (14) (15) (16) . It has been noted that Hh pathway activation and Smo receptor overexpression only occur in cancer-associated fibroblasts but not the neoplastic cells (17) . It was subsequently reported that targeting Hh pathway in murine models of PDA depletes stroma and sensitizes primary tumors to gemcitabine, leading to tumor shrinkage (18, 19) . However, targeting the Hh pathway in patients with PDA showed no additional benefit when added to the standard of care chemotherapy treatments (20) . 
Materials and Methods

Cell Culture
The murine pancreatic tumor cell lines-KPC and mCAF (mouse Cancer Associated Fibroblasts) were established in accordance with the Johns Hopkins Medical Institution Institutional Review Board (JHMI IRB)-approved protocols, and obtained between 2011 and 2015, and authenticated by DNA and gene expression profiling and cultured as previously described (24, 25). Briefly, cells were maintained in RPMI 1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% FBS (Gibco), 2 mM Lglutamine (Gibco), 1% non-essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), 50 units/mL penicillin and 50 μg/mL streptomycin (Gibco). The KPC cells were grown at 37ºC in 5% CO 2 .
Mouse models of PDA
All animal experiments conformed to the guidelines of the Animal Care and Use Committee of the Johns Hopkins University, and animals were maintained in accordance with the guidelines of the American Association of Laboratory Animal Care. All mice were monitored twice a day.
A genetically engineered mouse model of PDA, designated KPC mice, was previously established through a knock-in of pancreatic-specific, conditional alleles of the KRAS G12D and TP53 R172H mutations on a mixed 129/SvJae/C57Bl/6 background. The mouse pancreatic orthotopic model was described previously (27). In brief, 2 × 10 6 KPC cells were subcutaneously injected into the flanks of syngeneic female C57Bl/6 mice. After 1 to 2 weeks, the subcutaneous tumors were harvested and cut into ~1-mm 3 pieces. New syngeneic female C57Bl/6 mice, ages 8 to 10 weeks, were anesthetized. The abdomen was opened via a left subcostal incision. A small pocket was prepared inside the pancreas using microscissors, into which one piece of the subcutaneous tumor was implanted. The incision in the pancreas was closed with a suture. The abdominal wall was sutured, and the skin was adapted using wound clips.
c-Met and Hh inhibitor, and Gemcitabine treatments
For the in vivo studies, the Hedgehog signaling pathway inhibitor (28) NVP-LDE225 (provided by Novartis) was used at 50 mg/kg and the HGF/c-Met inhibitor INCB28060 (purchased from AbMole, Houston, TX, USA) (29, 30) was used at 1 mg/kg, both inhibitors were resuspended in DMSO. DMSO was used as a vehicle control for all treatments. The KPC and orthotopic transplant model mice were dosed daily by oral (31) gavage with NVP-LDE225, INCB28060, NVP-LDE225 + INCB28060 (at the same dose as their corresponsive single inhibitor treatments) or DMSO for 7, 14 or 21 days as indicated in the treatment schemas (Figure 1, 3 and 4) . In vitro experiments utilizing the above-mentioned inhibitors were previously described (25). Gemcitabine (SigmaAldrich, St. Lois, MO, USA) was reconstituted in deionized and distilled water at 20mg/ml and 100 μl administered via intraperitoneal injection into respective mice. 
TUNEL assay
The TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay was performed according to the manufacturer's instructions (Roche). Briefly, the slides were baked at 62.5˚C for 30 minutes to melt the paraffin. Following another 3 washes in PBS (5 minutes each), DAB was added to develop the reaction (10 minutes). Lastly, the slides were washed as above, dehydrated, mounted and subjected to analysis.
Immunohistochemistry and Immunofluorescence
Immunohistochemistry (IHC) staining for Shh, c-Met, E-Cadherin, IGF-1 and Ki67 were performed by hand. Tissue blocks with poor quality were excluded from the study. The slides for all stainings were hydrated; antigen retrieval was performed in a pressure cooker with citrate buffer (pH 6.0) for Shh and Ki67, in a steamer with citrate buffer (pH 6.0) for c-Met and IGF-1 and with Tris-EDTA buffer (pH 9.0) for E-Cadherin. Then, the slides were blocked in peroxidase, avidin and biotin block sequentially. Goat-anti-Shh (R&D), rabbit-anti-c-Met (Santa Cruz), rabbit anti-IGF-1 (Abcam), rabbit anti-ECadherin (Abcam), or rabbit anti-Ki67 (Abcam) primary antibodies at 1:50 (Shh, c-Met, E-Cadherin), 1: 500 (Ki67) and 4μg/ml (IGF-1) were added, and the slides were incubated for 1 hour at room temperature. Then, rabbit anti-goat or goat anti-rabbit biotinylated secondary antibodies (Vector Laboratories) respectively, were added for 30 minutes at room temperature. The signal was amplified and detected using the ABC Vectastain kit (Vector Laboratories) according to the manufacturer's instructions. The slides were developed using DAB and counterstained by hematoxylin. Lastly, the slides were dehydrated and mounted. All IHC slides were analyzed and scored by a pathologist. Immunofluorescence staining of c-Met and Shh was described in Supplementary Materials and Methods.
shRNA knockdown of c-Met
Viral supernatants were produced as previously described using shRNA against mouse cMet or scrambled shRNA control (Dharmacon) (27). Then, KPC cells were plated at 50% confluency and allowed to adhere for 24 hours. On the day of viral infection, the KPC media was aspirated and replaced with appropriately tittered viral supernatant (1ml/1 well of 6 well plate) with polybrene (8 μg/ml). The infection was allowed to proceed for 24 hours. After 24-hour infection, the cells were treated with appropriate inhibitors or vehicle control for additional 24 hours. Then, the cells were harvested and Annexin V expression was analyzed as previously described (32) . Knockdown of c-Met was confirmed by qRT-PCR as described below.
Quantitative real time RT-PCR
The RNeasy Micro Kit (Qiagen Inc, Valencia, CA, USA) was used to extract total RNA from cell pellets. The RNA was then converted to cDNA using the Superscript III First 
Co-culture assay
Treatment utilizing the transwell system (BD Biosciences, San Jose, CA, USA) was performed by plating KPC cells in the bottom chamber and mCAFs in the top chamber to spatially separate the cell types. c-Met was knockdown from KPC cells whereas the mCAFs were kept in a separate 6 well plate(s) during infection. After 24-hour infection the cells were treated in no serum media as previously described (25). After 24-hour treatment KPC cells were harvested and Annexin V analyzed.
Statistical analysis
Statistical analysis and graphing was performed using GraphPad Prism version 6.0 software (GraphPad Software, La Jolla, CA, USA). The data are presented as the means ± standard error of the mean (SEM). Student's t-test was used to compare differences between groups. Fisher's exact test was used to compare differences between treatment groups in the metastasis study and apoptosis study. For all analyses p value of less than 0.05 was considered statistically significant. orthotopic model for this part of the study, since it allows for the establishment of primary tumors of similar size (24). We previously showed that untreated mice become morbid and die between day 17 and day 25 with a median survival of 21 days (25).
Thus, following 2-week treatment (Figure 4A) , we chose to stop the experiment on day 19 before the majority of mice would have died, specifically, before there were no more than two dead mice in each treatment group. We euthanized all the mice and harvested their livers, gut, lungs and peritoneum for further analysis. Gross examination followed by histological examination of the metastasis formed revealed that single stromal agents in combination with gemcitabine show a trend in the reduction of metastases formation, which is in consistent with literature reports (34, 35) ( Figure 4C) . Importantly, the group with dual inhibitor treatment in addition to gemcitabine showed no metastases ( Figure   4C ). This result suggests that the combination of c-Met and Hh inhibitors in addition to gemcitabine has significantly suppressed metastasis formation.
Single c-Met or Hh inhibitor treatment leads to the enhanced expression of the other target and the combination of both c-Met and Hh inhibitors suppresses the expression of both targets more effectively
We then sought to understand the lack of effect of Hh or c-Met inhibition on primary tumor volume by examining the expression of their targets in PDAs from treated mice. We performed immunohistochemistry (IHC) staining on primary tumors from both the KPC (Figure 5A ) and the orthotopic ( Figure 5B ) mouse models that have been treated with gemcitabine alone or in combination with the inhibitors for one week ( Figure 1A) . As Moreover, no difference in the amount of IGF-1 was noted between the vehicle control and gemcitabine groups ( Figure 6B ). E-cadherin is downstream of both HGF/c-Met and Shh pathways (5, 25, 36) therefore, either inhibitor was able to activate E-cadherin. When both inhibitors were used, the expression of E-cadherin was higher than that seen with single inhibitors (Figure 6C ). Third, we tested the selectivity of c-Met inhibitor utilizing tumor cells with c-Met knockdown by shRNA. As shown in Table 1 This study not only confirms the prior finding but also provides an additional mechanistic explanation to the affectivity of dual stromal inhibition in terms of the decrease in PDA tumor burden. It also explains why single stromal agent clinical trials fail to show efficacy in human subjects (37) . One of the reasons is the development of resistance to those agents by overexpression of other, non-targeted pathways. We demonstrated that the upregulation of those non-targeted pro-tumorigenic pathways tends to be more prominent in longer-term treatments.
The use of PDA mouse models though very informative, has some limitations.
Mice with implanted tumors have a very short life span (~3 weeks) without treatments; thus we used the "two weeks" treatment course to mimic the long course of treatment.
Although KPC spontaneous tumor models could be treated for a longer course, we found that the mice could not tolerate a prolonged course of treatment with daily oral gavage and were concerned about inadvertent effect from oral gavage. Those limitations lead to difficulty in accessing survival benefit in these studies. Nevertheless, the data presented in these studies support further testing of the combination of Hh and c-Met inhibitors in clinical trials.
Numerous studies reported the benefit of stromal modulation in enhancing chemo sensitivity in mouse models of PDA (19, (38) (39) (40) (41) 
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Catenacci Mice in both models were treated for 1 week (as shown in Figure 1A ). The data is representative of 1 experiment. Mice that died before the completion of the planned treatment or whose quality of tumor was not adequate for analysis due to necrosis were 
